Table 5. Characteristics of groups with baseline CRP > 0.5 mg/dL and ≤ 0.5 g/dL.
Characteristics | Baseline CRP > 0.5 mg/dL n = 46 |
Baseline CRP ≤ 0.5 mg/dL n = 84 |
p-value | |
---|---|---|---|---|
Age (years) | 84 (80-88) | 83 (80-87) | 0.3 | |
Male sex | 53.7% | 48.7% | 0.6 | |
BMI (kg/m2) | 25.5 (23.3-27.2) | 25.3 (22.2-30.1) | 0.7 | |
NYHA FC IV heart failure | 61.0% | 29.5% | 0.001 | |
Diabetes mellitus | 31.7% | 38.5% | 0.5 | |
CAD | 58.5% | 51.3% | 0.4 | |
PVD | 26.8% | 23.1% | 0.6 | |
COPD | 14.6% | 5.1% | 0.09 | |
STS score (%) | 18.8 (7.7-26.6) | 6.9 (4.2-15.3) | 0.001 | |
LVEF (%) | 60 (44-68) | 66 (52-74) | 0.3 | |
Baseline creatinine (mg/dL) | 1.3 (0.9-1.5) | 1.1 (0.9-1,3) | 0.06 | |
Baseline hemoglobin (mg/dL) | 11.8 (10.0-13.2) | 12.1 (10,9-13.3) | 0.2 | |
Nadir hemoglobin (mg/dL) | 9.3 (8.0-10.9) | 9.9 (8.4-10.6) | 0.5 | |
Baseline platelets (x103/mm3) | 200 (145- 287) | 194 (165-226) | 0.4 | |
Nadir platelets (x103/mm3) | 149 (101-192) | 125 (102-152) | 0.04 | |
Peak CRP (mg/dL) | 11.5 (6.5-14.8) | 7.2 (4.6-10.3) | 0.002 | |
Aortic failure after TAVI ≥ +2/4 | 2.4% | 6.4% | 0.6 | |
Bleeding | Major | 14.6% | 25.6% | 0.2 |
Life-threatening | 9.8% | 6.4% | ||
Blood transfusion | 2 to 3 RBC units | 9.8% | 3.8% | 0.4 |
≥ 4 RBC units | 7.3% | 6.4% | ||
No ARF | 66.7% | 80.8% | 0.04 | |
ARF | Stage I | 25.6% | 17.9% | |
Stage II | 7.7% | 0% | ||
Stage III | 0% | 1.3% | ||
SIRS | 47.5% | 42.3% | 0.6 | |
New pacemaker | 26.8% | 21.8% | 0.6 |
hs-CRP: high sensitive C-reactive protein; BMI: body mass index; NYHA: New York Heart Association; FC: functional class; CAD: coronary artery disease; PVD: peripheral vascular disease; COPD: chronic obstructive pulmonary disease; STS: Society of Thoracic Surgeons; LVEF: left ventricle ejection fraction; TAVI: transcatheter aortic valve implantation; RBC: red blood cell; ARF: acute renal failure; SIRS: systemic inflammatory response syndrome. The Mann-Whitney test (numeric variables) and the chi-square or Fisher exact tests (categorical variables) were used.